Literature DB >> 25477583

Implementation of Polymerase Chain Reaction to Rule Out Clostridium difficile Infection Is Associated With Reduced Empiric Antibiotic Duration of Therapy.

William J Peppard1, Nathan A Ledeboer2.   

Abstract

PURPOSE: The polymerase chain reaction (PCR) test has higher sensitivity and a faster turnaround time than the enzyme immunoassay (EIA) for identification of Clostridium difficile, although the clinical implications of these variables are not well described.
METHODS: Inpatients with a negative EIA (n = 79) or PCR (n = 87) test were retrospectively evaluated. Patients were excluded if they had a positive EIA or PCR test during the same hospitalization or if they were currently receiving treatment for C. difficile infection (CDI) prior to admission. The primary outcome was empiric CDI antibiotic duration of therapy associated with each test method.
RESULTS: Empiric CDI antibiotic duration of therapy was 2.31 (95% confidence interval [CI], 1.48-3.15) days for the EIA group and 0.88 (0.45-1.33) days for the PCR group (P = .007). Number of diagnostic laboratory tests performed per patient were 2.73 (2.64-2.83) and 1.16 (1.04-1.28) tests, respectively (P < .001).
CONCLUSION: Use of the PCR test to rule out CDI was associated with reduced duration of empiric CDI antibiotic therapy and fewer diagnostic laboratory tests performed per patient. When combined with fewer diagnostic laboratory tests performed per patient and shorter duration of contact isolation, the higher acquisition cost of the PCR test was offset, resulting in cost neutrality. These findings provide additional data to support the routine use of the PCR test.

Entities:  

Keywords:  Clostridium difficile; antibiotic; enzyme immunoassay; polymerase chain reaction; stewardship

Year:  2014        PMID: 25477583      PMCID: PMC4252234          DOI: 10.1310/hpj4907-639

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  16 in total

1.  Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.

Authors:  Timothy H Dellit; Robert C Owens; John E McGowan; Dale N Gerding; Robert A Weinstein; John P Burke; W Charles Huskins; David L Paterson; Neil O Fishman; Christopher F Carpenter; P J Brennan; Marianne Billeter; Thomas M Hooton
Journal:  Clin Infect Dis       Date:  2006-12-13       Impact factor: 9.079

2.  Real-time PCR testing for CDI improves outcomes and reduces costs.

Authors:  Brian Currie
Journal:  MLO Med Lab Obs       Date:  2009-10

3.  Repeat stool testing to diagnose Clostridium difficile infection using enzyme immunoassay does not increase diagnostic yield.

Authors:  Abhishek Deshpande; Vinay Pasupuleti; Preethi Patel; Gati Ajani; Geraldine Hall; Bo Hu; Anil Jain; David D K Rolston
Journal:  Clin Gastroenterol Hepatol       Date:  2011-05-13       Impact factor: 11.382

4.  Fix the antibiotics pipeline.

Authors:  Matthew A Cooper; David Shlaes
Journal:  Nature       Date:  2011-04-07       Impact factor: 49.962

5.  Impact of isolation on hospital consumer assessment of healthcare providers and systems scores: is isolation isolating?

Authors:  Joan Vinski; Mary Bertin; Zhiyuan Sun; Steven M Gordon; Daniel Bokar; James Merlino; Thomas G Fraser
Journal:  Infect Control Hosp Epidemiol       Date:  2012-03-21       Impact factor: 3.254

Review 6.  Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options.

Authors:  Andrea Lo Vecchio; George M Zacur
Journal:  Curr Opin Gastroenterol       Date:  2012-01       Impact factor: 3.287

7.  Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile.

Authors:  Lorraine Kyne; Mary Beth Hamel; Rajashekhar Polavaram; Ciarán P Kelly
Journal:  Clin Infect Dis       Date:  2001-12-17       Impact factor: 9.079

8.  Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods.

Authors:  Kerrie Eastwood; Patrick Else; André Charlett; Mark Wilcox
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

9.  The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences.

Authors:  Judith A O'Brien; Betsy J Lahue; J Jaime Caro; David M Davidson
Journal:  Infect Control Hosp Epidemiol       Date:  2007-10-03       Impact factor: 3.254

Review 10.  Adverse outcomes associated with Contact Precautions: a review of the literature.

Authors:  Daniel J Morgan; Daniel J Diekema; Kent Sepkowitz; Eli N Perencevich
Journal:  Am J Infect Control       Date:  2009-03       Impact factor: 2.918

View more
  3 in total

1.  Point-Counterpoint: What Is the Optimal Approach for Detection of Clostridium difficile Infection?

Authors:  Ferric C Fang; Christopher R Polage; Mark H Wilcox
Journal:  J Clin Microbiol       Date:  2017-01-11       Impact factor: 5.948

2.  Clinical and economic impact of the introduction of a nucleic acid amplification assay for Clostridium difficile.

Authors:  Margaret M Guinta; Kristen Bunnell; Amanda Harrington; Susan Bleasdale; Larry Danziger; Eric Wenzler
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-12-04       Impact factor: 3.944

3.  Rapid and accurate diagnosis of Clostridium difficile infection by real-time polymerase chain reaction.

Authors:  Pil Hun Song; Jung Hwa Min; You Sun Kim; Soo Yeon Jo; Eun Jin Kim; Kyung Jin Lee; Jeonghun Lee; Hyun Sung; Jeong Seop Moon; Dong Hee Whang
Journal:  Intest Res       Date:  2018-01-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.